VJOncology is committed to improving our service to you

ASCO 2020 | Intracranial activity of selpercatinib in RET fusion positive NSCLC

VJOncology is committed to improving our service to you

Vivek Subbiah

Vivek Subbiah, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, described the LIBRETTO-001 study (NCT03157128), a phase I/II study of selpercatinib, a RET inhibitor, in patients with RET fusion positive NSCLC. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter